Drug intelligence / Profile preview

cyclophosphamide + lonidamine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of cyclophosphamide, an alkylating agent, and lonidamine, a glycolytic inhibitor. Cyclophosphamide works by slowing or stopping the growth of cancer cells, while lonidamine acts on mitochondria and inhibits energy metabolism in cancer cells. This combination aims to enhance anticancer effects by targeting both conventional cell killing mechanisms and cancer-specific metabolic pathways.

Targets

SDH (Mitochondrial electron transport chain complex II)MPTP (Mitochondrial permeability transition pore)

Beyond the preview

Go deeper on cyclophosphamide + lonidamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + lonidamine.

Explore the full profile